Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice

Journal of Dermatological Treatment

Volumn 18, Issue 2, 2007, Pages 76-83

  Berends, Maartje A M ^a   Driessen, Rieke J B ^a   Langewouters, Annechien M G ^a   Boezeman, Jan B ^a   Van De Kerkhof, Peter C M ^a   De Jong, Elke M G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Clinical practice; Efalizumab; Etanercept; High need psoriasis

Indexed keywords

CORTICOSTEROID; DITHRANOL; EFALIZUMAB; ETANERCEPT; ETRETIN; FUMARIC ACID; ISONIAZID; METHOTREXATE; VITAMIN D DERIVATIVE;

ABDOMINAL PAIN; ACTINIC KERATOSIS; ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; BASAL CELL CARCINOMA; BLEPHARITIS; BOWEN DISEASE; CHILL; CLINICAL ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ECZEMA; EDEMA; EPISTAXIS; ESOPHAGUS CARCINOMA; EYE INFECTION; EYE IRRITATION; FATIGUE; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; LEUKOCYTOSIS; LOWER RESPIRATORY TRACT INFECTION; MALE; MOLLUSCA CONTAGIOSA; MOUTH INFECTION; MYALGIA; MYCOSIS; NAUSEA; OTALGIA; OUTPATIENT; PHOTODERMATOSIS; PHOTOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURIGO; PRURITUS; PSEUDOFOLLICULITIS BARBAE; PSORIASIS; RECTUM HEMORRHAGE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; SWEATING; THROMBOCYTOPENIA; TREATMENT DURATION; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BIOLOGICAL RESPONSE MODIFIERS; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34249062065     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630601121086     Document Type: Article

References (14)

1. Wyeth Europe Ltd MUK. Enbrel® summary of product characteristics. 2005.
2. Enbrel® (etanercept). Full prescribing information [package insert]. Thousand Oaks, CA: Immunex Corp; 2006.
3. Raptiva® (efalizumab). Full prescribing information [package insert]. South San Francisco, CA: Genentech Inc; 2005.
4. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003;139:1627-32.
5. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014-22.
6. Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, Nakanishi AM, et al. A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304-12.
7. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, et al. Efalizumab for patients with moderate to severe plaque psoriasis: A randomized controlled trial. JAMA. 2003;290:3073-80.
8. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.N Engl JMed. 2003;349:2004-13.
9. Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, et al. Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial. J Am Acad Dermatol. 2005;52(3 Pt 1):425-33.
10. Papp KA, Bressinck R, Fretzin S, Goffe B, Kempers S, Gordon KB, et al. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: A phase IIIb, randomized, controlled trial. Int J Dermatol. 2006;45:605-14.
11. Dubertret L, Sterry W, Bos JD, Chimenti S, Shumack S, Larsen CG, et al. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: Results from a phase III international randomized, placebo-controlled trial. Br J Dermatol. 2006;155:170-81.
12. Van der HD, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006;54:1063-74.
13. Taban M, Dupps WJ, Mandell B, Perez VL. Etanercept (enbrel)-associated inflammatory eye disease: Case report and review of the literature. Ocul Immunol Inflamm. 2006;14:145-50.
14. Carey W, Glazer S, Gottlieb AB, Lebwohl M, Leonardi C, Menter A, et al. Relapse, rebound, and psoriasis adverse events: An advisory group report. J Am Acad Dermatol. 2006;54(4 Suppl 1):S171-81.